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ABSTRACT
The binding of ligands to death receptors elicits distinct outcomes, such as apoptosis, inflammation and
necroptosis, depending on the cellular context. We have recently described that the autophagic protein
TP53INP2 favors apoptosis upon death receptor signaling and is a potential biomarker of responsiveness
10 to TRAIL treatment.
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Apoptosis, a highly regulated cellular suicide program, is
common and conserved among metazoans. Various factors
can induce apoptosis, among them death receptor ligands Fas
ligand (FasL), tumor necrosis factor alpha (TNFα) and TNF
15 related apoptosis inducing ligand (TRAIL) via death receptor
oligomerization (Fas, TNF alpha receptor (TNFαR), death
receptor 3 (DR3), death receptor 4 (DR4), and death receptor
5 (DR5)).1 The triggering of death receptors by their ligands
recruits numerous molecules to the forming intracellular
20 complex, which in turn leads to two cellular outcomes, survi-
val or death. Many studies have sought to identify compo-
nents of these complexes that would favor the latter outcome,
especially since the discovery of TRAIL ligand and its unique
capacity to induce apoptosis in cancer cells without harming
25 normal cells. Unfortunately, several clinical trials have failed
due to the poor stability of soluble TRAIL protein and tumor
resistance to TRAIL monotherapy. Consequently, there is
a growing need for new therapeutic strategies.2
We have recently reported a new regulator of death recep-
30 tor signaling, namely the autophagy protein TP53INP2
(tumor protein p53-inducible nuclear protein 2).3 We used
several apoptotic inducers to identify the role of this protein
in apoptosis and autophagy crosstalk. Our data showed that
TP53INP2 sensitizes cancer cells to death receptor-induced
35 apoptosis by acting as a scaffold for efficient ubiquitination of
caspase-8 by TNF receptor-associated factor 6 (TRAF6).
Furthermore, TP53INP2 and another autophagy protein,
p62, aggregate ubiquitinated caspase-8 through their respec-
tive ubiquitin binding motifs to fully activate it.3,4 It is still
40 unclear whether TP53INP2 is sufficient to aggregate ubiqui-
tinated caspase-8. However, this function is in synergy with
p62, as p62 knock-down only partially rescued death receptor-
induced apoptosis. By screening several breast and liver can-
cer cell lines, we found a positive correlation between
45 TP53INP2 protein levels and susceptibility of cancer cells to
TRAIL. These findings thus identify TP53INP2 as a potential
biomarker to distinguish patients who would benefit from
TRAIL therapy.3
TP53INP2 is an intrinsically disordered protein involved
50in nuclear hormone receptor signaling, obesity, diabetes
and autophagy.5–7 The function of TP53INP2 in death
receptor signaling per se is independent of autophagy.
However, the re-localization of this protein to the plasma
membrane in response to TRAIL is likely to lower the
55amount of the protein available for autophagy, thus down-
regulating autophagic flux and further favoring apoptosis.
Indeed, a recent study showed that TP53INP2 regulates
autophagy by acting as a scaffold for the lipidation of
Microtubule-associated protein 1A/1B-light chain 3 (LC3)
60by Autophagy related 7 (ATG7).8 The engagement of key
autophagic proteins in apoptosis has the following advan-
tages: (i) it facilitates the induction of apoptosis; and (ii) it
sequesters autophagic proteins from their function in
autophagy. Along the same lines, various studies have
65shown that targeting autophagy is a promising strategy to
overcome TRAIL resistance in several types of cancer.9
Furthermore, most autophagic proteins are cleaved after
fulfilling their function of activating caspases in apoptosis,
thereby impeding their role in autophagy and hence further
70favoring apoptosis. The same is true for TP53INP2 (Figure
1). After activation of caspase-8, and probably caspase-3,
TP53INP2 is cleaved. The caspase cleavage sites in
TP53INP2 are around the LC3 interacting region (LIR)
sequence at D33, D39 and D42 (Figure 1). D33 and D42
75are putative caspase-3 cleavage sites, while D39 is a putative
caspase-8 cleavage site. The caspase that cleaves TP53INP2
first has not been identified to date; however, in the case of
death receptor-induced apoptosis, we speculate that cas-
pase-8 cleaves TP53INP2 at D39, thus cutting off the
80N-terminal part with the LIR sequence from the rest of
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the protein and probably abrogating its role in autophagy.
Later, when caspase-3 is activated, additional cleavage(s) at
D33 and D42 might take place, completely isolating the LIR
sequence (W35-I38) from the rest of TP53INP2 (Figure 1).
85 It would be interesting to address whether cleavage at D39
by caspase-8 is enough to completely abrogate the function
of TP53INP2 in autophagy, especially since it was shown
that ATG7 binds to first 28 amino acids of TP53INP2. In
addition, it is not clear if 1–39 amino acids long fragment
90 of TP53INP2 is sufficient to facilitate LC3 lipidation.8
Nevertheless, when caspase-3 is activated, the function of
TP53INP2 in autophagy is abrogated. Moreover, the
N-terminal caspase cleavage parts that still have the LIR
sequence might further interfere with LC3 function in
95 autophagy by omitting its binding to autophagy cargo
receptor proteins like p62 or Neighbor of BRCA1 gene 1
(NBR1).7
Autophagy signaling is almost invariably induced in
response to TRAIL, and extensive studies have shown that
100 autophagy is one of the mechanisms that causes resistance to
TRAIL monotherapy.9 Thus, inhibiting autophagy would
have a synergistic effect when combined with TRAIL
treatment. In fact, TP53INP2 sensitization to TRAIL might
go in the same direction as TP53INP2 engagement in death
105receptor signaling and its cleavage by caspases most probably
lowers autophagic flux. It would be interesting to examine
whether TP53INP2 can also sensitize cancer cells that are
intrinsically resistant to TRAIL-induced apoptosis, as occurs
in mutant K-RAS (KRAS) expressing lung adenocarcinomas,
110in which TRAIL monotherapy could have pro-tumorigenic
and pro-metastatic functions.10 We speculate that, in this
specific cellular context, TP53INP2 would sensitize cells to
therapy combining autophagy inhibitors and TRAIL treat-
ment. Further studies will reveal the specific cellular contexts
115in which TP53INP2 can be a potential biomarker for TRAIL
monotherapy or combined therapies with TRAIL for perso-
nalized cancer treatments.
Hopefully, our recent study will shed some light on how
to stratify cancer patients most likely to benefit from
120TRAIL treatment. Notably, autophagy inhibitors in combi-
nation with other standard chemotherapies like TRAIL are
in various cancer clinical trials. Hence, we consider that
TP53INP2 is a potential biomarker for TRAIL mono- or
combined therapy.
Figure 1. Role TP53INP2 in TRAIL-induced apoptosis. In basal condition TP53INP2 is localized in nucleus or in cytoplasm, where with LC3 has a function in basal
autophagy. Upon TRAIL addition, TP53INP2 re-localizes to plasma membrane where acts as a scaffold for caspase-8 ubiquitination by TRAF6. Ubiquitinated caspase-8
is aggregated by p62 and TP53INP2 for its full activation, thus leading to apoptosis. Activated caspase-8 and effector caspases can cleave TP53INP2 at various
aspartates (D) around the LIR sequence. The cleavage of TP53INP2 probably abrogates its function in autophagy and some of the possible N-terminal caspase
cleavage fragments with LIR motif might further downregulate autophagy. LC3, Microtubule-associated protein 1A/1B-light chain 3; LIR, LC3 interacting region;
TRAIL, Tumor necrosis factor (TNF) related apoptosis inducing ligand; TRAIL-R, TNF related apoptosis inducing ligand receptor; TRAF6, TNF receptor-associated factor
6, TP53INP2, tumor protein p53-inducible nuclear protein 2.
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Atg7 Autophagy related 7
DR3 death receptor 3
DR4 death receptor 4
DR5 death receptor 5
FasL Fas ligand
KRAS K-RAS
LC3 Microtubule-associated protein 1A/1B-light chain 3
LIR LC3 interacting region
NBR1 Neighbor of BRCA1 gene 1
TNFα tumor necrosis factor alpha
TNFαR TNF alpha receptor
TRAIL TNF related apoptosis inducing ligand
TRAF6 TNF receptor-associated factor 6
TP53INP2 tumor protein p53-inducible nuclear protein 2
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